Ping2joseph
2021-09-08
[Strong]
EMA Says Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":880488168,"tweetId":"880488168","gmtCreate":1631072075654,"gmtModify":1632884794825,"author":{"id":3578387522492131,"idStr":"3578387522492131","authorId":3578387522492131,"authorIdStr":"3578387522492131","name":"Ping2joseph","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Strong] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Strong] </span><br></p></body></html>","text":"[Strong]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/880488168","repostId":2164871841,"repostType":2,"repost":{"id":"2164871841","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1630666361,"share":"https://ttm.financial/m/news/2164871841?lang=&edition=full","pubTime":"2021-09-03 18:52","market":"us","language":"en","title":"EMA Says Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=2164871841","media":"T-Reuters","summary":"EMA:Ema: Meeting Highlights From The Pharmacovigilance Risk Assessment Committee (Prac) 30 August – ","content":"<html><body><p>EMA:Ema: Meeting Highlights From The Pharmacovigilance Risk Assessment Committee (Prac) 30 August – 2 September 2021: 03/09/2021.Ema Says Covid-19 Vaccines: Ema Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot.Ema Says Some Cases Of Mis Were Also Reported In Eea Following Vaccination With Other Covid-19 Vaccines.Ema: At This Stage, There Is No Change To The Current Eu Recommendations For The Use Of Covid-19 Vaccines.Ema: Prac Is Reviewing Data On Cases Of Venous Thromboembolism (Blood Clots In The Veins) With Covid-19 Vaccine Janssen..Ema - Will Now Assess Available Data On Mis To Determine Whether Condition Can Be Caused By Vaccine And Recommend Whether Any Changes To Product Info.Ema: Prac To Assess Additional Data From 2 Large Clinical Trials Of Vaccine, Which Are To Be Submitted Shortly By Marketing Authorisation Holder Of Vaccine Janssen.Ema - Prac Discussed A Direct Healthcare Professional Communication (Dhpc) Containing Important Safety Information For Imbruvica..Ema: Prac Reviewing Signal For Patients With Cll Currently Receiving Ibrutinib Plus Rituximab Together With Ace Inhibitor, Advises Reconsider Treatment Strategy.Ema Says Venous Thromboembolism Was Included In The Risk Management Plan For Covid-19 Vaccine Janssen As A Safety Issue To Be Investigated.Ema-For Patients With Cll On Ace-Inhibitors Who Have Not Yet Started Treatment With Ibrutinib Plus Rituximab, Treatment Strategy Should Be Reconsidered.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMA Says Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMA Says Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-09-03 18:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>EMA:Ema: Meeting Highlights From The Pharmacovigilance Risk Assessment Committee (Prac) 30 August – 2 September 2021: 03/09/2021.Ema Says Covid-19 Vaccines: Ema Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot.Ema Says Some Cases Of Mis Were Also Reported In Eea Following Vaccination With Other Covid-19 Vaccines.Ema: At This Stage, There Is No Change To The Current Eu Recommendations For The Use Of Covid-19 Vaccines.Ema: Prac Is Reviewing Data On Cases Of Venous Thromboembolism (Blood Clots In The Veins) With Covid-19 Vaccine Janssen..Ema - Will Now Assess Available Data On Mis To Determine Whether Condition Can Be Caused By Vaccine And Recommend Whether Any Changes To Product Info.Ema: Prac To Assess Additional Data From 2 Large Clinical Trials Of Vaccine, Which Are To Be Submitted Shortly By Marketing Authorisation Holder Of Vaccine Janssen.Ema - Prac Discussed A Direct Healthcare Professional Communication (Dhpc) Containing Important Safety Information For Imbruvica..Ema: Prac Reviewing Signal For Patients With Cll Currently Receiving Ibrutinib Plus Rituximab Together With Ace Inhibitor, Advises Reconsider Treatment Strategy.Ema Says Venous Thromboembolism Was Included In The Risk Management Plan For Covid-19 Vaccine Janssen As A Safety Issue To Be Investigated.Ema-For Patients With Cll On Ace-Inhibitors Who Have Not Yet Started Treatment With Ibrutinib Plus Rituximab, Treatment Strategy Should Be Reconsidered.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164871841","content_text":"EMA:Ema: Meeting Highlights From The Pharmacovigilance Risk Assessment Committee (Prac) 30 August – 2 September 2021: 03/09/2021.Ema Says Covid-19 Vaccines: Ema Reviewing Cases Of Multisystem Inflammatory Syndrome Relating To Pfizer Shot.Ema Says Some Cases Of Mis Were Also Reported In Eea Following Vaccination With Other Covid-19 Vaccines.Ema: At This Stage, There Is No Change To The Current Eu Recommendations For The Use Of Covid-19 Vaccines.Ema: Prac Is Reviewing Data On Cases Of Venous Thromboembolism (Blood Clots In The Veins) With Covid-19 Vaccine Janssen..Ema - Will Now Assess Available Data On Mis To Determine Whether Condition Can Be Caused By Vaccine And Recommend Whether Any Changes To Product Info.Ema: Prac To Assess Additional Data From 2 Large Clinical Trials Of Vaccine, Which Are To Be Submitted Shortly By Marketing Authorisation Holder Of Vaccine Janssen.Ema - Prac Discussed A Direct Healthcare Professional Communication (Dhpc) Containing Important Safety Information For Imbruvica..Ema: Prac Reviewing Signal For Patients With Cll Currently Receiving Ibrutinib Plus Rituximab Together With Ace Inhibitor, Advises Reconsider Treatment Strategy.Ema Says Venous Thromboembolism Was Included In The Risk Management Plan For Covid-19 Vaccine Janssen As A Safety Issue To Be Investigated.Ema-For Patients With Cll On Ace-Inhibitors Who Have Not Yet Started Treatment With Ibrutinib Plus Rituximab, Treatment Strategy Should Be Reconsidered.","news_type":1,"symbols_score_info":{"PFE":1}},"isVote":1,"tweetType":1,"viewCount":422,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/880488168"}
精彩评论